Glioblastoma multiforme is an aggressive malignant brain tumor. The monoclonal antibody, bevacizumab, is active in recurrent disease via inhibition of angiogenesis. Proteinuria and renal thrombotic microangiopathy are known complications. We report a case of a patient developing acute renal failure with biopsy-proven interstitial nephritis while receiving bevacizumab for recurrent disease. The patient was otherwise well with a history of controlled hypertension. Renal function improved with discontinuation of bevacizumab and the administration of corticosteroid therapy.
StuppRMasonWPvan den BentMJ. Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. N Engl J Med2005; 352: 997–1003.
2.
StuppRHegiMEMasonWP. Effects of radiotherapy with concomitant and adjuvant temozolamide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol2009; 10(5): 459–466.
3.
ChamberlainM. Bevacizumab for the treatment of recurrent glioblastoma. Oncology2011; 5: 117–129.
4.
Avastin [package insert]. South San Francisco, CA: Genetech Inc, May 2009.
5.
FriedmanHSPradosMDWenPY. Bevacizumab alone and in combination with irinotecan in recurrent glioblastom. J Clin Oncol2009; 27: 4733–4740.
6.
MathewTH. The Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust2005; 183(3): 138–141.
7.
GurevichFPerazellaM. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med2009; 122: 322–328.
8.
SchrijversBFlyvbjergAVrieseA. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int2004; 65: 2003–2017.
9.
EreminaVJeffersonJAKowalewskaJ. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med2008; 358: 1129–1136.
10.
BarakatRKSinghNLalR. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma. Ann Pharmacother2007; 41(4): 707–710.
11.
NaranjoCABustoUSellersEM. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther1981; 30: 239–245.
